ArticleDermatology and therapy2025
Efficacy of 5-Fluorouracil 4% Cream in the Treatment of Hyperkeratotic Actinic Keratosis: A Single-Center Retrospective Real-World Study.
Article in Dermatology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionActinic keratosis (AK) is recognized as the main precursor of cutaneous squamous cell carcinoma (cSCC). Given the unpredictable potential for progression, current guidelines recommend treating all AKs, irrespective of their clinical grade. However, many approved treatments are not indicated for hyperkeratotic AKs. Among topical therapies, 5-fluorouracil (5-FU) 4% cream (Tolak®/Tolerak®; Pierre Fabre) is a chemotherapeutic agent that has shown excellent results in treating non-hyperkeratotic AKs on the face, ear, and scalp, both in clinical trials and real-life experiences. However, its effectiveness in managing hyperkeratotic AKs remains unexplored.
methodsA retrospective, single-center study was conducted at the Dermatology Unit of the University of Messina, Italy, between September 2024 and March 2025. The study included 66 hyperkeratotic AK lesions in 19 consecutive patients, treated with 5-FU cream for 28 consecutive days.
resultsAt the 3-month follow-up, total clearance (complete lesion resolution) was observed in 54.5% of hyperkeratotic lesions, while partial clearance (> 75% lesion reduction) was recorded in 24.2%. The treatment demonstrated a good safety profile, with good patient tolerability. Among local skin reactions (LSRs), erythema was the most frequently observed, occurring in 89.5% of patients, followed by stinging, which was reported in 73.6% of cases. No patient discontinued the treatment as a result of the onset of adverse events.
conclusionsOur findings, albeit initial, support the efficacy and safety of 5-FU 4% cream for the treatment of hyperkeratotic AKs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.